La Jol­la shares whacked as an­a­lysts spot­light dis­ap­point­ing PhI­II fine print

Last Feb­ru­ary, shares of La Jol­la Phar­ma­ceu­ti­cal $LJPC rock­et­ed up on the news that its lead drug hit its pri­ma­ry end­point in Phase III. At …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.